Current therapies for multiple sclerosis (MS) inhibit the inflammatory response, but neither sufficiently inhibits ongoing degeneration within the brain nor provide potential repair to injured brain tissue. Consequently, there are no therapies with demonstrated efficacy in slowing, stopping, or reversing the progressive stage of MS, therefore representing an extreme unmet need in neurologic disease. Complicating matters, there are no biological or imaging markers with demonstrated utility for use in Phase 2 trials to screen putative therapies for progressive MS. This study proposes to both test the activity of a potential neuroprotection therapy - ibudilast - in progressive MS and test several candidate imaging measures for their utility in future studies of neuroprotection in progressive MS. We plan to conduct a 2-year;placebo-controlled trial of ibudilast in progressive MS. Multiple advanced imaging modalities will be used to evaluate the activity of ibudilast. At the conclusion of the tril, we will have a clear understanding of the effect of ibudilast on advanced imaging metrics and its safety and potential clinical benefit in progressive MS. Through additional analyses, we will determine which imaging metric provides the most robust and practical outcome for implementation in future clinical trials in progressive MS. Hopefully, this study will show efficac of ibudilast that leads to the first primary neuroprotective drug. Even if ibudilast is not found beneficial, the study will be crucial to the MS field by comparing imaging metrics to support practical Phase II trials for a group of MS patients for whom there is no treatment option.
Progressive multiple sclerosis (MS) is a gradually progressive form of MS affecting approximately 200,000 Americans and is the leading cause of non-traumatic neurologic disability in young adults. There are both no therapies with demonstrated efficacy in progressive MS and no validated biomarkers to screen potential therapies in small, efficient proof-of-concept trials. This trial will both evaluate the activity a putative neuroprotetive therapy in a phase II clinical trial in progressive MS and also evaluate several potential imaging biomarkers to identify the most robust imaging measure of neurodegeneration. The results will have broad relevance to other neurodegenerative disorders.
|Sakaie, Ken; Zhou, Xiaopeng; Lin, Jian et al. (2018) Technical Note: Retrospective reduction in systematic differences across scanner changes by accounting for noise floor effects in diffusion tensor imaging. Med Phys :|
|Simuni, Tanya; Caspell-Garcia, Chelsea; Coffey, Christopher S et al. (2018) Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort. J Neurol Neurosurg Psychiatry 89:78-88|
|Fox, Robert J; Coffey, Christopher S; Conwit, Robin et al. (2018) Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis. N Engl J Med 379:846-855|
|Zhou, Xiaopeng; Sakaie, Ken E; Debbins, Josef P et al. (2018) Scan-rescan repeatability and cross-scanner comparability of DTI metrics in healthy subjects in the SPRINT-MS multicenter trial. Magn Reson Imaging 53:105-111|
|Ontaneda, Daniel; Thompson, Alan J; Fox, Robert J et al. (2017) Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. Lancet 389:1357-1366|
|Zhou, Xiaopeng; Sakaie, Ken E; Debbins, Josef P et al. (2017) Quantitative quality assurance in a multicenter HARDI clinical trial at 3T. Magn Reson Imaging 35:81-90|
|Sakaie, Ken; Lowe, Mark (2017) Retrospective correction of bias in diffusion tensor imaging arising from coil combination mode. Magn Reson Imaging 37:203-208|
|Fox, Robert J; Chataway, Jeremy (2017) Advancing trial design in progressive multiple sclerosis. Mult Scler 23:1573-1578|
|Lowe, Mark J; Sakaie, Ken E; Beall, Erik B et al. (2016) Modern Methods for Interrogating the Human Connectome. J Int Neuropsychol Soc 22:105-19|
|Fox, Robert J; Coffey, Christopher S; Cudkowicz, Merit E et al. (2016) Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. Contemp Clin Trials 50:166-77|